174 related articles for article (PubMed ID: 24898091)
1. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.
Waldron-Lynch F; Kareclas P; Irons K; Walker NM; Mander A; Wicker LS; Todd JA; Bond S
BMJ Open; 2014 Jun; 4(6):e005559. PubMed ID: 24898091
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
3. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
4. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Heywood J; Evangelou M; Goymer D; Kennet J; Anselmiova K; Guy C; O'Brien C; Nutland S; Brown J; Walker NM; Todd JA; Waldron-Lynch F
Trials; 2015 Mar; 16():86. PubMed ID: 25881192
[TBL] [Abstract][Full Text] [Related]
5. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
6. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E; Howlett J; Porter L; Truman L; Heywood J; Kennet J; Arbon EL; Anselmiova K; Walker NM; Atkar R; Pekalski ML; Rytina E; Evans M; Wicker LS; Todd JA; Mander AP; Bond S; Waldron-Lynch F
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282826
[TBL] [Abstract][Full Text] [Related]
7. Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial.
Zhao TX; Kostapanos M; Griffiths C; Arbon EL; Hubsch A; Kaloyirou F; Helmy J; Hoole SP; Rudd JHF; Wood G; Burling K; Bond S; Cheriyan J; Mallat Z
BMJ Open; 2018 Sep; 8(9):e022452. PubMed ID: 30224390
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A; Bensimon G; Payan CA; Jacqueminet S; Bourron O; Nicolas N; Fonfrede M; Rosenzwajg M; Bernard C; Klatzmann D
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):295-305. PubMed ID: 24622415
[TBL] [Abstract][Full Text] [Related]
9. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
10. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
11. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.
Yu A; Snowhite I; Vendrame F; Rosenzwajg M; Klatzmann D; Pugliese A; Malek TR
Diabetes; 2015 Jun; 64(6):2172-83. PubMed ID: 25576057
[TBL] [Abstract][Full Text] [Related]
12. Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.
Yang JH; Cutler AJ; Ferreira RC; Reading JL; Cooper NJ; Wallace C; Clarke P; Smyth DJ; Boyce CS; Gao GJ; Todd JA; Wicker LS; Tree TI
Diabetes; 2015 Nov; 64(11):3891-902. PubMed ID: 26224887
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 and type 1 diabetes: new therapeutic perspectives.
Hartemann A; Bourron O
Diabetes Metab; 2012 Nov; 38(5):387-91. PubMed ID: 22771204
[TBL] [Abstract][Full Text] [Related]
14. IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA; Buckner JH; Greenbaum CJ
Clin Immunol; 2013 Dec; 149(3):324-31. PubMed ID: 23499139
[TBL] [Abstract][Full Text] [Related]
15. Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes.
Williams JH; Udata C; Ganguly BJ; Bucktrout SL; Joh T; Shannon M; Wong GY; Levisetti M; Garzone PD; Meng X
AAPS J; 2020 Jan; 22(2):23. PubMed ID: 31900603
[TBL] [Abstract][Full Text] [Related]
16. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
17. Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.
Dwyer CJ; Ward NC; Pugliese A; Malek TR
Curr Diab Rep; 2016 Jun; 16(6):46. PubMed ID: 27076179
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
19. Treatment of type 1 diabetes by regulatory T-cell infusion via regulating the expression of inflammatory cytokines.
Wang G; Yan Y; Xu N; Yin D; Hui Y
J Cell Biochem; 2019 Dec; 120(12):19338-19344. PubMed ID: 31535398
[TBL] [Abstract][Full Text] [Related]
20. Isolation and enrichment of mouse insulin-specific CD4
Đedović N; Paunović V; Stojanović I
J Immunol Methods; 2019 Jul; 470():46-54. PubMed ID: 31039339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
